{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:24:24Z","timestamp":1761920664501},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2010,2,26]],"date-time":"2010-02-26T00:00:00Z","timestamp":1267142400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1186\/2047-783x-15-2-81","type":"journal-article","created":{"date-parts":[[2019,12,10]],"date-time":"2019-12-10T21:46:23Z","timestamp":1576014383000},"source":"Crossref","is-referenced-by-count":3,"title":["Raltegravir, tenofovir, and emtricitabine in an HIV-Infected patient with HCV chronic hepatitis, NNRTI intolerance and protease inhibitors-induced severe liver toxicity"],"prefix":"10.1186","volume":"15","author":[{"given":"F","family":"Ortu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"LE","family":"Weimer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Floridia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"PE","family":"Manconi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,2,26]]},"reference":[{"key":"280_CR1","doi-asserted-by":"publisher","first-page":"3713","DOI":"10.3748\/wjg.15.3713","volume":"15","author":"AK Singal","year":"2009","unstructured":"Singal AK, Anand BS: Management of hepatitis C virus infection in HIV\/HCV co-infected patients: clinical review. World J Gastroenterol 2009, 15: 3713\u20133724. 10.3748\/wjg.15.3713","journal-title":"World J Gastroenterol"},{"key":"280_CR2","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1097\/COH.0b013e3281ca6fd2","volume":"2","author":"M Vogel","year":"2007","unstructured":"Vogel M, Rockstroh JK: Hepatotoxicity and liver disease in the context of HIV therapy. Curr Opin HIV AIDS 2007, 2: 306\u2013313. 10.1097\/COH.0b013e3281ca6fd2","journal-title":"Curr Opin HIV AIDS"},{"key":"280_CR3","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1097\/COH.0b013e328122dbaa","volume":"2","author":"UA Walker","year":"2007","unstructured":"Walker UA: Antiretroviral therapy-induced liver alterations. Curr Opin HIV AIDS 2007, 2: 293\u2013298. 10.1097\/COH.0b013e328122dbaa","journal-title":"Curr Opin HIV AIDS"},{"issue":"17","key":"280_CR4","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1097\/00002030-200411190-00008","volume":"18","author":"MS Sulkowski","year":"2004","unstructured":"Sulkowski MS, Mehta SH, Chaisson RE, Thomas DL, Moore RD: Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir. AIDS 2004,18(17):2277\u20132284. 10.1097\/00002030-200411190-00008","journal-title":"AIDS"},{"key":"280_CR5","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1310\/hct0905-309","volume":"9","author":"JA Pineda","year":"2008","unstructured":"Pineda JA, P\u00e9rez-El\u00edas MJ, Pe\u00f1a JM, Luque I, Rodr\u00edguez-Alcantara F: Fosamprenavir Expanded Access Program Group. Low rate of adverse hepatic events associated with fosamprenavir\/ritonavir-based antiretroviral regimens. HIV Clin Trials 2008, 9: 309\u2013313. 10.1310\/hct0905-309","journal-title":"HIV Clin Trials"},{"key":"280_CR6","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.biopha.2006.12.005","volume":"62","author":"Dj Jevtovic","year":"2008","unstructured":"Jevtovic Dj, Ranin J, Salemovic D, et al.: The prevalence and risk of hepatitis flares in a Serbian cohort of HIV and HCV co-infected patients treated with HAART. Biomed Pharmacother 2008, 62: 21\u201325. 10.1016\/j.biopha.2006.12.005","journal-title":"Biomed Pharmacother"},{"issue":"4","key":"280_CR7","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1093\/jac\/dkn045","volume":"61","author":"JA Pineda","year":"2008","unstructured":"Pineda JA, Santos J, Rivero A, Abdel-Kader L, Palacios R, Camacho A, Lozano F, Mac\u00edas J, Liverey Study Investigator Team: Liver toxicity of antiretroviral combinations including atazanavir\/ritonavir in patients co-infected with HIV and hepatitis viruses: impact of pre-existing liver fibrosis. J Antimicrob Chemother 2008,61(4):925\u2013932. 10.1093\/jac\/dkn045","journal-title":"J Antimicrob Chemother"},{"key":"280_CR8","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/S0140-6736(07)60597-2","volume":"369","author":"B Grinsztejn","year":"2007","unstructured":"Grinsztejn B, Nguyen BY, Katlama C, Gatell JM, Lazzarin A, Vittecoq D, et al.: Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518. in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet 2007, 369: 1261\u20131269. 10.1016\/S0140-6736(07)60597-2","journal-title":"Lancet"},{"key":"280_CR9","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.2165\/00003495-200969080-00007","volume":"69","author":"JD Croxtall","year":"2009","unstructured":"Croxtall JD, Keam SJ: Raltegravir: a review of its use in the management of HIV infection in treatment-experienced patients. Drugs 2009, 69: 1059\u20131075. 10.2165\/00003495-200969080-00007","journal-title":"Drugs"},{"key":"280_CR10","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1056\/NEJMoa0708975","volume":"24","author":"RT Steigbigel","year":"2008","unstructured":"Steigbigel RT, Cooper DA, Kumar PN, Eron JE, Schechter M, Markowitz M, et al.: Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008, 24: 339\u2013354.","journal-title":"N Engl J Med"},{"key":"280_CR11","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1089\/aid.2006.22.825","volume":"22","author":"MJ N\u00fa\u00f1ez","year":"2006","unstructured":"N\u00fa\u00f1ez MJ, Mart\u00edn-Carbonero L, Moreno V, Valencia E, Garcia-Samaniego J, Castillo JG, Barreiro P, Gonz\u00e1lez-Lahoz J, Soriano V: Impact of antiretroviral treatment-related toxicities on hospital admissions in HIV-infected patients. AIDS Res Hum Retroviruses 2006, 22: 825\u2013829. 10.1089\/aid.2006.22.825","journal-title":"AIDS Res Hum Retroviruses"},{"key":"280_CR12","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1310\/hct0706-319","volume":"7","author":"R Palacios","year":"2006","unstructured":"Palacios R, Vergara S, Rivero A, Aguilar I, Mac\u00edas J, Camacho A, Lozano F, Garc\u00eda-L\u00e1zaro M, Pineda JA, Torre-Cisneros J, M\u00e1rquez M, Santos J: Low incidence of severe liver events in HIV patients with and without hepatitis C or B coinfection receiving lopinavir\/ritonavir. HIV Clin Trials 2006, 7: 319\u2013323. 10.1310\/hct0706-319","journal-title":"HIV Clin Trials"},{"key":"280_CR13","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1111\/j.1468-1293.2004.00232.x","volume":"5","author":"P Meraviglia","year":"2004","unstructured":"Meraviglia P, Schiavini M, Castagna A, Vigan\u00f2 P, Bini T, Landonio S, Danise A, Moioli MC, Angeli E, Bongiovanni M, Hasson H, Duca P, Cargnel A: Lopinavir\/ritonavir treatment in HIV antiretroviral-experienced patients: evaluation of risk factors for liver enzyme elevation. HIV Med 2004, 5: 334\u2013343. 10.1111\/j.1468-1293.2004.00232.x","journal-title":"HIV Med"},{"key":"280_CR14","volume-title":"J Antimicrob Chemother","author":"E Vispo","year":"2009","unstructured":"Vispo E, Mena A, Maida I, Blanco F, Cordoba M, Labarga P, et al.: Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C. J Antimicrob Chemother 2009, in press."}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/2047-783X-15-2-81.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/2047-783X-15-2-81\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/2047-783X-15-2-81.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,10]],"date-time":"2019-12-10T21:46:24Z","timestamp":1576014384000},"score":1,"resource":{"primary":{"URL":"https:\/\/eurjmedres.biomedcentral.com\/articles\/10.1186\/2047-783X-15-2-81"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2,26]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["280"],"URL":"https:\/\/doi.org\/10.1186\/2047-783x-15-2-81","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,2,26]]},"article-number":"81"}}